|
|
|
|
|
Click Here to return To Results
|
|
|
|
The values of age, disease duration, Expanded Disability Status Scale (EDSS) score, the number of T1- and T2-weighted lesions, and their volume were similar between GA- and placebo-receiving groups at the entry of this study. There was a decrease in the number of T1-enhanced lesions (p = 0.03) and a significant percent annual decrease of their volume in GA recipients compared with those of placebo recipients. There were no significant differences between changes in the two groups in the number of T2 lesions and their volume. The loss of brain tissue was significantly smaller in the GA group compared with that of the placebo group. These results show that GA treatment may decrease both lesion inflammation and the rate of brain atrophy i n RR-MS. |
|
(click to filter results - removes previous filter)
cerebral cortical atrophy
cop 1
disability rating scale,neurological
gadolinium
MRI
MRI,abnormal
MRI,contrast enhanced
MRI,volumetry
multiple sclerosis
multiple sclerosis,relapsing
multiple sclerosis,treatment of
treatment of neurologic disorder
|
Click Here to return To Results
|
|